Table 3.
Anti-hypertensive (anti-HTN) drugs distribution
| Characteristic/Variable | Non-T2D group (n = 15) | T2D group (n = 10) | p-value |
|---|---|---|---|
| Total anti-HTN drugs* | 3.3 ± 0.5 [3.1 - 3.6] | 4.1 ± 0.7 [3.6 - 4.6] | 0.02 |
| Thiazide diuretic | 100% (15) | 100% (10) | - |
| Aldosterone receptor inhibitor | 26.6% (4) | 50% (5) | 0.40 |
| Angiotensin converting enzyme inhibitor | 66.6% (10) | 50% (5) | 0.68 |
| Angiotensin receptor blocker | 40% (6) | 70% (7) | 0.23 |
| Calcium channel blocker | 86.6% (13) | 100% (10) | 0.50 |
| Centrally acting anti-hypertensive drug | 6.6% (1) | 40% (4) | 0.12 |
The values are expressed as means ± standard deviation; [95% confidence interval]; (*) Statistical significance (p < 0.05). Non-T2D: non type 2 diabetes resistant hypertension; T2D: type 2 diabetes resistant hypertension.